Evidence map›Paper›PMID 39089348›Full record

ArticleClinical immunology (Orlando, Fla.)2024

Patient subtyping analysis of baseline multi-omic data reveals distinct pre-immune states associated with antibody response to seasonal influenza vaccination.

Cigdem Sevim Bayrak, Christian V Forst, Drew R Jones, David J Gresham, Smruti Pushalkar, Shaohuan Wu, Christine Vogel, Lara K Mahal, Elodie Ghedin, Ted Ross and 2 more

Abstract read
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Cigdem Sevim BayrakDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mt Sinai, New York, NY, USA; Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: cigdem.sevimbayrak@mssm.edu.
Christian V ForstDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mt Sinai, New York, NY, USA; Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Microbiology, Icahn School of Medicine at Mt Sinai, New York, NY, USA.
Drew R JonesDepartment of Biochemistry and Molecular Pharmacology, New York University Langone Health, NY, New York, USA.
David J GreshamCenter for Genomics and Systems Biology, Department of Biology, New York University, New York, NY, USA.
Smruti PushalkarCenter for Genomics and Systems Biology, Department of Biology, New York University, New York, NY, USA.
Shaohuan WuCenter for Genomics and Systems Biology, Department of Biology, New York University, New York, NY, USA.
Christine VogelCenter for Genomics and Systems Biology, Department of Biology, New York University, New York, NY, USA.
Lara K MahalDepartment of Chemistry, University of Alberta, Edmonton, Alberta, Canada.
Elodie GhedinSystems Genomics Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD, USA.
Ted RossCenter for Vaccines and Immunology, University of Georgia, Athens, GA, USA; Department of Infectious Diseases, University of Georgia, Athens, GA, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bin ZhangDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mt Sinai, New York, NY, USA; Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: bin.zhang@mssm.edu.

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)U19AI168631 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Viviana A Simon · 2022 to 2026
$14.4M
Genomic profiling of influenza infections to identify biomarkers of disease severityZIAAI001323 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GHEDIN, ELODIE · 2020 to 2025
$8.0M
Deciphering the Heterogeneous Response to Influenza by a Multi-Scale Systems ApproachR01AI170112 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHRISTIAN FORST · 2022 to 2026
$3.1M
NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI170112NIAID NIH HHS U19 AI168631
6 · The paper itself

Abstract

Understanding the molecular mechanisms underpinning diverse vaccination responses is critical for developing efficient vaccines. Molecular subtyping can offer insights into heterogeneous nature of responses and aid in vaccine design. We analyzed multi-omic data from 62 haemagglutinin seasonal influenza vaccine recipients (2019-2020), including transcriptomics, proteomics, glycomics, and metabolomics data collected pre-vaccination. We performed a subtyping analysis on the integrated data revealing five subtypes with distinct molecular signatures. These subtypes differed in the expression of pre-existing adaptive or innate immunity signatures, which were linked to significant variation in baseline immunoglobulin A (IgA) and hemagglutination inhibition (HAI) titer levels. It is worth noting that these differences persisted through day 28 post-vaccination, indicating the effect of initial immune state on vaccination response. These findings highlight the significance of interpersonal variation in baseline immune status as a crucial factor in determining the effectiveness of seasonal vaccines. Ultimately, incorporating molecular profiling could enable personalized vaccine optimization.

Indexed as

Antibodies, ViralInfluenza, HumanInfluenza VaccinesMultiomicsVaccinationAdaptive ImmunityAntibody FormationHemagglutination Inhibition TestsHumansImmunity, InnateImmunoglobulin AProteomicsSeasonsAntibodies, ViralImmunoglobulin AInfluenza VaccinesAntibody responseExisting immunityInfluenzaMolecular subtypingMulti-omic integrationVaccine

Identifiers

PMID39089348
PMCPMC11340208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.